Related Experiment Video
Updated: Jun 25, 2026
Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing
Published on: November 29, 2018
Unfinished business: Incomplete laminin processing exposes a tumor target
1Vascular Biology Program, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. jacqueline.banyard@childrens.harvard.edu
Abstract:
The G45 domain of laminin-332 is cleaved in normal tissues but remains in squamous cell carcinomas. Targeting this domain using a G45 antibody reduced in vivo tumor growth and invasion and suggests a role for G45 as a new therapeutic target.
Insights
The G45 domain of laminin-332, usually cleaved in healthy tissues, persists in squamous cell carcinomas. An antibody targeting G45 inhibited tumor growth and invasion, identifying G45 as a potential therapeutic target.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Laminin-332 is a crucial extracellular matrix protein involved in cell adhesion and tissue integrity.
- The G45 domain of laminin-332 undergoes cleavage in normal tissues.
- Aberrant presence of the G45 domain is observed in squamous cell carcinomas.
Purpose of the Study:
- To investigate the role of the G45 domain of laminin-332 in squamous cell carcinoma progression.
- To evaluate the therapeutic potential of targeting the G45 domain.
Main Methods:
- Utilized antibody-based targeting of the G45 domain.
- Assessed the impact on tumor growth and invasion in vivo models.
Main Results:
- The G45 domain was found to be retained in squamous cell carcinomas, unlike in normal tissues.
- In vivo administration of a G45 antibody significantly reduced tumor growth.
- Targeting G45 also diminished tumor invasion.
Conclusions:
- The G45 domain of laminin-332 plays a role in the progression of squamous cell carcinomas.
- G45 represents a promising new therapeutic target for squamous cell carcinoma treatment.
